Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with induction chemotherapy followed by response-adapted radiotherapy or chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
ChiCTR2000041139Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimotuzumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Disease-free survival rate. Started Dec 2020; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2000041139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041139.